Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dena Krishnan

Internal Medicine Suffolk, VA Doctor of Osteopathy

NPI 1720372428 CMS profile 1124489

5838 Harbour View Blvd Ste 270, Suffolk, VA 23435

Open in the dashboard

General payments

$2,280

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dena Krishnan of Suffolk, VA is reported in the CMS Open Payments database as having received $2,280 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 2
2024 General $48 2
2023 General $445 23
2022 General $281 16
2021 General $484 27
2020 General $207 12
2019 General $767 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dena Krishnan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dena Krishnan were reported at $47. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dena Krishnan Internal Medicine median Middle half National median
2019 $767 $159 $48–$570 $163
2020 $207 $119 $33–$402 $114
2021 $484 $135 $37–$521 $132
2022 $281 $141 $42–$496 $149
2023 $445 $149 $45–$519 $160
2024 $48 $154 $47–$537 $164
2025 $47 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $350 23 payments
  2. Janssen Pharmaceuticals, Inc $320 21 payments
  3. Amgen Inc. $216 14 payments
  4. iRhythm Technologies, Inc. $175 1 payment
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $135 11 payments
  6. Pfizer Inc. $130 7 payments
  7. Astellas Pharma US Inc $100 1 payment
  8. Medtronic, Inc. $98 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $93 4 payments
  10. E.R. Squibb & Sons, L.L.C. $90 6 payments
  11. Other $573 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,180 123 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $320 21 payments
  2. ENTRESTO $260 17 payments
  3. Repatha $216 14 payments
  4. ZIO Patch $175 1 payment
  5. LifeVest $135 11 payments
  6. Corlanor $122 8 payments
  7. JARDIANCE $93 4 payments
  8. ELIQUIS Cardiovascular;Metabolic Disease $85 5 payments
  9. ELIQUIS Cardiovascular $73 5 payments
  10. VERQUVO $68 4 payments
  11. Other $823 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,720

Median for Cardiology: 2,533

Drug cost

$323,387

Median for Cardiology: $485,213

Branded share of claims

24.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 121 $135,433
Xarelto Rivaroxaban Brand 55 $62,203
Entresto Sacubitril/Valsartan Brand 56 $57,870
Repatha Sureclick Evolocumab Brand 27 $23,882
Repatha Pushtronex Evolocumab Brand 25 $19,149
Repatha Syringe Evolocumab Brand 19 $11,018
Metoprolol Succinate Generic 158 $2,401
Atorvastatin Calcium Generic 144 $1,404
Rosuvastatin Calcium Generic 78 $1,170
Carvedilol Generic 153 $1,024

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$164,416

Of which drugs: $3,786

Medicare patients

1,365

Average age 76

Services billed

2,998

785 women, 580 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 46%
Ischemic heart disease 42%
Chronic kidney disease 40%
Heart failure 37%
Atrial fibrillation 29%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 88 352 $2,207
Injection, perflutren lipid microspheres, per ml Q9957 Office 23 49 $1,579

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record